Hemophilia Management: Emergency Stabilization and Long-Term Strategies

Written by Margaret Anne Rockwood | Last updated August 6th, 2026
Medically reviewed by Shannon Walker, MD

When managing hemophilia, it is crucial to recognize bleeds and treat them appropriately. Although advances in bleed prevention, gene therapies, and non-factor therapies have transformed outcomes, acute bleeding episodes remain medical emergencies.

In cases of major trauma, gastrointestinal hemorrhage, retroperitoneal bleeding, or intracranial hemorrhage, patients may require substantial blood product support in addition to hemostatic therapy. However, the primary treatment goal is rapid correction of the underlying coagulation defect rather than transfusion alone.

Treat First, Diagnose Second

Emergency management calls for treatment before diagnostic evaluation can be completed due to the time-sensitive nature of stopping significant bleeding. Individuals with hemophilia often carry individualized treatment plans or emergency care cards that specify factor replacement products and dosing recommendations to help guide treatment. These plans should be followed whenever available.

However, the absence of a care card or family or clinical history can sometimes mean treating broadly. Emergency medicine physicians should maintain a high index of suspicion because significant bleeding may occur with relatively minor trauma. In patients with known or suspected hemophilia, factor replacement should be initiated promptly for serious bleeding or high-risk bleeding sites, even before laboratory results are available, as delays in treatment can increase morbidity. This approach is particularly critical in cases of head injury, intracranial hemorrhage, neck or airway bleeding, gastrointestinal bleeding, retroperitoneal hemorrhage, major trauma, or rapidly expanding hematomas.

Hallmark Signs and Primary Treatment

Joint hemorrhage remains the most common bleeding manifestation in severe hemophilia. Acute hemarthrosis typically presents with pain, warmth, and decreased range of motion. Early factor replacement reduces joint damage and improves long-term outcomes. Clinicians should also promptly evaluate suspected intracranial hemorrhage, which remains one of the most serious complications and, again, requires immediate factor replacement before proceeding with other diagnostic steps such as imaging, whenever clinically feasible.

Most hemophilia bleeds do not require massive transfusion. In severe trauma or uncontrolled hemorrhage, patients may instead require:

• packed red blood cells
  • fresh frozen plasma (FFP, rarely when factor concentrates are unavailable)
  • platelets if thrombocytopenic
  • factor VIII or IX replacement
  • bypassing agents, if inhibitors are present
  • antifibrinolytics such as tranexamic acid or aminocaproic acid

No Known Inhibitor

For patients with hemophilia A or B without inhibitors, treatment consists of prompt administration of factor VIII or factor IX concentrates to achieve hemostatic levels. Invasive procedures should not be performed until adequate factor replacement has been administered.

For selected patients with mild hemophilia A and documented responsiveness, desmopressin (DDAVP) may be appropriate for non-life-threatening bleeding episodes.

Suspicion of an Inhibitor

Most patients with inhibitors carry emergency treatment plans or medical alert cards that identify the presence of inhibitors and specify preferred bypassing therapy because standard factor replacement may be ineffective. If inhibitor status is unknown but the patient has a history of hemophilia and fails to respond appropriately to factor replacement, consultation with a hemophilia treatment center is warranted because an inhibitor should be suspected.

Bypassing agents such as recombinant activated factor VII are commonly used in these patients. Recombinant activated factor VII (rFVIIa) bypasses the intrinsic pathway by directly activating factor X on the surface of activated platelets, generating sufficient thrombin to produce stable fibrin clot formation even when factor VIII or IX has been neutralized by inhibitors. Typically, factors VIII and IX help generate factor Xa through the intrinsic coagulation pathway. Inhibitors neutralize infused factor VIII or IX, making standard replacement ineffective.

Recombinant activated factor VII (rFVIIa) bypasses the need for factors VIII and IX by directly activating factor X on activated platelet surfaces, leading to sufficient thrombin to form a stable clot despite the inhibitor. Thus, it is called a “bypassing agent” because it bypasses the missing or inhibited coagulation factors.

Emerging evidence suggests that breakthrough bleeding in patients with Hemophilia A who take prophylactic emicizumab (a bispecific monoclonal antibody that mimics factor VIII activity), can also be effectively managed with recombinant activated factor VII. Emicizumab (Hemlibra, Genentech) restores factor VIII-like cofactor activity but does not normalize thrombin generation in all clinical situations, particularly during major trauma or surgery. Recombinant activated factor VII remains effective because it activates coagulation downstream of the emicizumab-mediated pathway, augmenting thrombin generation independently of factor VIII.

Recent quality-improvement studies have highlighted persistent challenges in emergency departments, where time to factor administration often exceeds recommended targets. Rapid-access protocols and readily available clotting factor products can substantially reduce treatment delays.

Ongoing Care and Long-Term Management

The goal of contemporary hemophilia care is prevention of bleeding rather than treatment of bleeding after it occurs. The World Federation of Hemophilia considers prophylaxis the only strategy capable of altering the natural history of the disease by preventing recurrent bleeding and progressive joint destruction.

Routine pharmacologic prophylaxis to prevent bleeding remains standard of care for patients with severe hemophilia and for those with clinically significant bleeding phenotypes. Long-term, such prophylaxis dramatically reduces spontaneous bleeding, preserves joint function, and improves quality of life. Extended-half-life factor concentrates have further reduced treatment burden by decreasing infusion frequency, with many factor IX products administered every 1 to 2 weeks and some factor VIII products requiring only one to two infusions per week.

The introduction of emicizumab is one of the most important advances in hemophilia A.  Emicizumab is a bispecific monoclonal antibody that mimics factor VIII activity. Administered subcutaneously, emicizumab has demonstrated substantial reductions in annualized bleeding rates in patients both with and without inhibitors. Long-term follow-up studies have shown durable bleed protection and favorable safety profiles.

Unlike factor VIII concentrates, emicizumab does not induce factor VIII inhibitors because it is not factor VIII. Anti-drug antibodies against emicizumab occur in fewer than 1% of treated patients, and only a small proportion are neutralizing or clinically significant enough to reduce efficacy.

Emicizumab mimics factor VIII activity but does not completely normalize coagulation. Patients can still experience breakthrough bleeding from trauma, surgery, or severe spontaneous hemorrhage.

rFVIIa remains effective because it activates coagulation downstream of both the missing factor VIII and the emicizumab pathway.

Note that activated prothrombin complex concentrate (aPCC) should generally be avoided or used cautiously with emicizumab because of reported thrombotic microangiopathy and thrombotic complications.

Challenges Tied to Factor VIII and IX Alloimmunity

Approximately 25% to 35% of individuals with severe hemophilia A disease and 3% to 10% with hemophilia B develop inhibitors. Most inhibitors develop during the first 20 to 50 exposure days to factor concentrate.

Individuals with alloimmunity have historically been particularly complex to treat, having associations with increased bleeding and disability. Modern preventive approaches along with  bypassing strategies have largely changed this practice.

For example, patients with hemophilia A who historically experienced recurrent debilitating bleeds now have dramatically lower bleeding rates with the use of emicizumab-based prophylaxis. Emicizumab is a bispecific monoclonal antibody that, to a large degree, performs the amplifier role factor VIII plays in the clotting cascade by building an artificial bridge between factors IXa and X.

There is no emicizumab-like factor VIII-mimetic drug for hemophilia B, but non-factor therapies such as fitusiran (Qfitlia, Sanofi), which lowers antithrombin, and anti-TFPI antibodies such as marstacimab (Hympavzi, Pfizer) provide additional prophylactic options for selected patients with hemophilia A or B.

With these preventives as a foundation, additional limitations related to factor VIII or IX inhibitors may be largely overcome through the individualized use of:

• recombinant factor VIIa
  • activated prothrombin complex concentrate (when appropriate)
  • careful monitoring of bleed location and severity
  • surgical planning protocols
  • multidisciplinary management through hemophilia treatment centers

Whole Patient Care

Comprehensive care extends beyond hemostatic therapy. Regular musculoskeletal assessment is essential to address chronic synovitis, arthropathy, pain, and disability that can arise from repeated hemarthroses. Physical therapy, exercise programs, and orthopedic interventions may be required to maintain function.

In addition, individuals with hemophilia should undergo routine monitoring for inhibitor development, treatment adherence, and psychosocial challenges. Multidisciplinary care through specialized hemophilia treatment centers has consistently been associated with improved outcomes.

Sources

• Alblaihed L, et al. High risk and low prevalence diseases: hemophilia. Am J Emerg Med. 2022.
• Aledort L, et al. Factor VIII replacement is still the standard of care in hemophilia A. Blood Rev. 2019.
• Alexander WA, et al. Bleeding in patients with hemophilia who have inhibitors. Hematology Am Soc Hematol Educ Program. 2022.
• Bhat R, et al. Evaluation and management of congenital bleeding disorders in the emergency department. Clin Pediatr Emerg Med. 2017.
• Blair HA. Emicizumab: a review in hemophilia A. Drugs. 2019.
• Jiménez-Yuste V, et al. Management of urgent bleeding in patients with hemophilia A. J Clin Med. 2024.
• Mahlangu J, et al. Long-term outcomes with emicizumab in hemophilia A without inhibitors. Blood Adv. 2024.
• Mahlangu J, et al. Marstacimab for the treatment of hemophilia A or B. 2025.
• Mancuso ME, et al. Extended half-life clotting factor concentrates in hemophilia: clinical experience and future perspectives. Blood Rev. 2023.
• Mendes ACS, et al. Gene therapy in the treatment of hemophilia A. Curr Opin Hematol. 2026.
• Muniz RL, et al. Emicizumab prophylaxis in hemophilia A: a systematic review and meta-analysis. Haemophilia. 2023.
• National Bleeding Disorders Foundation Medical and Scientific Advisory Council (MASAC). Guidelines for Emergency Department Management of Individuals With Hemophilia and Other Bleeding Disorders. Published 2019.
• Pipe SW. Hemophilia: new therapies for hemophilia. Hematology Am Soc Hematol Educ Program. 2016.
• Sahu S, et al. Revisiting hemophilia management in acute medicine. J Emerg Trauma Shock. 2011.
• Srivastava A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(suppl 6):1-158.
• U.S. Food and Drug Administration. FDA approves novel treatment for hemophilia A or B, with or without factor inhibitors. Published 2025.
• Young G. Emerging non-factor therapies for hemophilia. Hematology Am Soc Hematol Educ Program. 2024.
• World Federation of Hemophilia. Guidelines for the Management of Hemophilia: 3rd Edition—2024 Update. Published 2024.